Harmony Biosciences Holdings Inc (HRMY)

$39.05 +0.51 (1.32%)
Market Cap 2.20B
Revenue (ttm) 582.02M
Net Income (ttm) 128.85M
EPS (ttm) N/A
PE Ratio 17.26
Forward PE 11.93
Profit Margin 22.14%
Debt to Equity Ratio 0.31
Volume 658,900
Avg Vol 540,476
Day's Range N/A - N/A
Shares Out 57.03M
Stochastic %K 92%
Beta 0.78
Analysts Strong Sell
Price Target $51.00

Latest News on HRMY

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

Jan 13, 2025, 8:05 AM EST - 4 days ago

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Dec 18, 2024, 8:05 AM EST - 4 weeks ago

HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT

Dec 3, 2024, 8:05 AM EST - 6 weeks ago

HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Nov 21, 2024, 8:05 AM EST - 2 months ago

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Nov 11, 2024, 4:57 PM EST - 2 months ago

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

Oct 30, 2024, 10:30 PM EDT - 2 months ago

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders

Oct 29, 2024, 5:15 PM EDT - 2 months ago

Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 1:43 PM EDT - 2 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024

Oct 16, 2024, 8:05 AM EDT - 3 months ago

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY

Oct 1, 2024, 8:45 AM EDT - 3 months ago

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY

HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024

Sep 26, 2024, 8:05 AM EDT - 4 months ago

HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024

Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says

Sep 10, 2024, 2:56 PM EDT - 4 months ago

Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says

Harmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline Potential

Aug 19, 2024, 1:58 PM EDT - 5 months ago

Harmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline Potential

Harmony Biosciences: Advancing An Expanded Pipeline

Aug 15, 2024, 10:36 AM EDT - 5 months ago

Harmony Biosciences: Advancing An Expanded Pipeline

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:06 PM EDT - 5 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call Transcript

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

Aug 6, 2024, 7:30 AM EDT - 5 months ago

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024

Jul 23, 2024, 8:05 AM EDT - 6 months ago

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024

HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)

Jun 25, 2024, 8:05 AM EDT - 7 months ago

HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY

Jun 24, 2024, 7:00 AM EDT - 7 months ago

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1

Jun 5, 2024, 8:05 AM EDT - 8 months ago

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE

May 28, 2024, 8:05 AM EDT - 8 months ago

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE